COVID-19 Novel Molecular Point of Care Diagnostics Evaluation

• ClinicalTrials.gov Identifier: NCT06055218
• Recruitment Status: Completed
• First Posted: September 26, 2023
• Last Update Posted: October 5, 2023
• Sponsor: Foundation for Innovative New Diagnostics, Switzerland
• Information provided by (Responsible Party): Foundation for Innovative New Diagnostics, Switzerland

Study Description

Brief Summary:

Point estimates of sensitivity and specificity of molecular POC platforms for SARS-CoV-2, with 95% confidence intervals, using RT-PCR as reference standard.

Condition or disease
COVID-19 Respiratory Infection

Detailed Description:

The aim of this study is to independently evaluate the performance of novel molecular point-of-care (POC) assays for the direct detection of SARS-CoV-2 nucleic acid (RNA) in comparison to the current reference standard, laboratory-based real-time reverse-transcription PCR (RT-PCR), for use to diagnose COVID-19, a serious and sometimes fatal respiratory infection caused by the coronavirus SARS-CoV-2. A total of 3 molecular POC devices, detecting SARS-CoV-2 and other viral pathogens, have been selected by FIND through open calls for expressions of interest. These are Covid/RSV/Flu Nudge Test (DnaNudge Ltd, Nudge test from hereon), Test Kit for SARS-CoV-2 RNA Detection in Biological Material Using PCR Method (Mirai Genomics, Mirai test from hereon) and GenomEra (Abacus Diagnostica Oy, GenomEra test from hereon). Other molecular POC devices currently in the late development stage may become available for assessment of clinical performance at later time, should these pass FIND's selection criteria.

The COVID-19 pandemic has rapidly spread across the globe. As of 3 October 2022, there are approximately a total of 623 million confirmed cases reported worldwide, that resulted in a total of 6.55 million deaths. The current weekly incidence is on average 1 million new cases. However, the consensus among public health officials is that the number of infected individuals is far higher. Given the wide range of possible symptoms and the potential for transmission before individuals are aware that they are infected, exposure to SARS-CoV-2 is a particular hazard for health care providers. Though diagnostic capacity has greatly improved due to the introduction of novel antigen rapid diagnostic tests (Ag RDT), long turnaround times for results of the current reference standard for testing (RT-PCR) is still a major challenge. This impacts on the ability of public health officials to track and contain the disease. The lack of capacity, in turn, is due in part to the logistic challenges and global reagent shortages faced by laboratories attempting to implement new RT-PCR assays for SARS-CoV-2.

Rapid sample-in-answer-out molecular POC devices, if shown to have sufficient accuracy to aid in clinical decision-making, could contribute substantially to control the disease spread globally. Molecular POC devices might provide a source of immediate diagnostic testing in low-and middle-income countries unable to implement RT-PCR due to lack of sample transport and storage facilities at local laboratories.

Study Design

• Study Type: Observational
• Actual Enrollment: 600 participants
• Observational Model: Other
• Time Perspective: Prospective
• Official Title: Evaluation of the Performance of Novel Molecular Point of Care Diagnostics for SARS-CoV-2
• Actual Study Start Date: January 30, 2023
• Actual Primary Completion Date: April 11, 2023
• Actual Study Completion Date: August 30, 2023

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

1. Sensitivity and Specitivity [ Time Frame: at enrollement ]
   Point estimates of sensitivity and specificity of molecular POC platforms

Secondary Outcome Measures :

1. Sensitivity and specificity in specific subgroups [ Time Frame: at enrolment ]
   Point estimates of sensitivity and specificity of molecular POC platforms for SARS-CoV-2, with 95% confidence intervals, using RT-PCR as reference standard.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Specimens to be tested for this study must originate from adult symptomatic individuals (≥ 18 years old) suspected to have COVID-19 (as per national or WHO case definitions).

Criteria

Inclusion Criteria: Participants and specimens are eligible to be included in the study only if all the following inclusion criteria apply:

• Adult individuals (≥18 years of age) with symptoms suggesting plausible COVID-19 infection (as per WHO or national clinical case definitions)
• Individuals who have voluntarily given written consent to participate in this study or who have given their written consent for their specimen to be used for future research studies
• Individuals able to provide the specimens required for the study

Exclusion Criteria:

• Individuals on oxygen therapy
• Individuals with recent history of excessive nose bleeds
• Individuals with hemodynamic instability as determined by their treating physician
• Individuals already enrolled in other clinical studies, where similar respiratory specimens are collected on the same day.

Contacts and Locations

Locations

Switzerland

University Hospital of Geneva

Geneva, Switzerland, 1211

Uganda

Central Public Health Laboratories

Kampala, Uganda, 759125

United Kingdom

Liverpool school of Topical Medicine

Liverpool, United Kingdom, L35QA

Sponsors and Collaborators

Foundation for Innovative New Diagnostics, Switzerland

Investigators

• Study Chair: Camille Escadafal; FIND Diagnostics

More Information

• Responsible Party: Foundation for Innovative New Diagnostics, Switzerland
• ClinicalTrials.gov Identifier: NCT06055218
• Other Study ID Numbers: CV010
• First Posted: September 26, 2023
• Last Update Posted: October 5, 2023
• Last Verified: October 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

COVID-19; Respiratory Tract Infections; Pneumonia, Viral; Pneumonia; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases